Lead Products:
• BFPET – Myocardial perfusion imaging
• CardioPET – Cardiac viability assessment
• VasoPET – Inflamed atherosclerotic plaque imaging
Clinical Benefits:
• Current methods do not assess myocardial health
• Higher diagnostic accuracy
• Alternative to invasive procedures
FluoroPharma Advantage:
• Proprietary products that support new technologies for personalized medicine
• Two Phase II ready products with short study timelines, both directed to very large markets
• Robust pipeline of first-in-class imaging products
• Technology compatible with current clinical practice, with reliable reimbursement in place
• Clear and focused plan of value creation
• Experienced management and world-class advisors
• Intellectual property in place to protect proprietary innovations around the world
Growing Market:
• Global market for imaging agents expected to exceed $15 billion by 2015
• Increasing demand for personalized medicine
• Growing volume of diagnostic exams and associated equipment sales
• Aging population expanding commercialization potential
• Global spread of new technologies, with Asia-Pacific and other high growth markets
• Drive for cost effective analysis to avoid unnecessary or inappropriate operations
For more information, see the company website at www.FluoroPharma.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
